載入中
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
收盤時
US$46.92
+US$0.42 · +0.90%
盤後
US$46.96
+US$0.04 · +0.09%
10月12日 下午7:22 ET
盤中時間採用ET。市場資料可能有所延遲。
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
日內區間
目前US$46.92
52週區間
目前US$46.92
盤中時間採用ET。市場資料可能有所延遲。
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
日內區間
目前US$46.92
52週區間
目前US$46.92
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（GBP） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 326.67億 GBP | 313.76億 GBP | 303.28億 GBP | 293.24億 GBP | 246.96億 GBP |
| 銷貨成本 | 90.17億 GBP | 90.48億 GBP | 85.65億 GBP | 95.54億 GBP | 81.63億 GBP |
| 毛利 | 236.5億 GBP | 223.28億 GBP | 217.63億 GBP | 197.7億 GBP | 165.33億 GBP |
| 研究與開發 | 75.25億 GBP | 64.01億 GBP | 62.23億 GBP | 54.88億 GBP | 50.19億 GBP |
| 銷售、一般及管理費用 | 90.88億 GBP | 110.15億 GBP | 93.85億 GBP | 83.72億 GBP | 70.7億 GBP |
| 營業費用 | 153.12億 GBP | 183.07億 GBP | 150.18億 GBP | 133.37億 GBP | 121.76億 GBP |
| 利息收入 | 5600萬 GBP | 6739.2萬 GBP | 4000萬 GBP | 6426.5萬 GBP | 2800萬 GBP |
| 利息支出 | 6.87億 GBP | 6.58億 GBP | 7.75億 GBP | 8.56億 GBP | 7.84億 GBP |
| 折舊和攤銷 | 23.14億 GBP | 25.51億 GBP | 22.94億 GBP | 21.47億 GBP | 21.22億 GBP |
| 營業利益 | 83.38億 GBP | 40.21億 GBP | 67.45億 GBP | 64.33億 GBP | 43.57億 GBP |
| 淨利 | 57.16億 GBP | 25.75億 GBP | 49.28億 GBP | 149.56億 GBP | 43.85億 GBP |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
State Street SPDR Portfolio Developed World ex-US ETFSPDW1.14億0.28%404.62億 USD0.03%US$49.69-0.58%
Avantis International Equity ETFAVDE6736.68萬0.35%192.24億 USD0.23%US$89.58-0.24%
Fidelity Enhanced International ETFFENI5260.47萬0.46%114.7億 USD0.28%US$39.63-0.15%
VanEck Pharmaceutical ETFPPH4465.86萬4.28%10.37億 USD0.36%US$110.7+0.19%
First Trust Value Line Dividend Index FundFVD2928.55萬0.38%76.22億 USD0.62%US$47.97+0.65%
GMO International Value ETFGMOI1509.96萬2.30%6.54億 USD0.60%US$39.17-0.03%
Hartford Multifactor Developed Markets (ex-US) ETFRODM1422.34萬0.88%16.15億 USD0.29%US$40.75-0.17%
Avantis International Large Cap Value ETFAVIV1067.89萬0.53%20.24億 USD0.25%US$78.96-0.05%State Street SPDR Portfolio Developed World ex-US ETFSPDWAvantis International Equity ETFAVDEFidelity Enhanced International ETFFENIVanEck Pharmaceutical ETFPPHFirst Trust Value Line Dividend Index FundFVDGMO International Value ETFGMOIHartford Multifactor Developed Markets (ex-US) ETFRODMAvantis International Large Cap Value ETFAVIVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
